Voorbehandeling met chemotherapie, verwarmde buikspoeling met chemotherapie na chirugische verwijdering van alle tumor bij patienten met buikvlies uizaaiingen van dikke darm of endeldarm kanker.

Recruiting

Conditions: peritoneal metastasis, colorectal cancer, surgery, cytoreduction,HIPECperitoneaal metastasen, chirurgie, neo-adjuvante chemotherapie, cytoreductie, HIPEC

Registration Number: NL-OMON22353

Lead Sponsor: niversity Medcal Center Groningen

Brief Summary: /A

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 50

Inclusion Criteria

1. Peritoneal carcinomatosis of colorectal origin diagnosed either at laparotomy or by malignant ascites on CT-scan. When ascites is diagnosed, cytologic confirmation of peritoneal carcinomatosis is sufficient. At laparotomy either histologic or cytologic confirmation of peritoneal carcinomatosis is sufficient;

2. Age of 18 years of older;

Exclusion Criteria

1. Previous chemotherapy except adjuvant chemotherapy with an interval between the end of adjuvant chemotherapy and the start of neo-adjuvant chemotherapy of at least 12 months;

2. History of other malignancy, exept basal cell carcinoma;

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Efficacy of neo-adjuvant chemotherapy with respect to the percentage of patients who are resectable after neo-adjuvant chemotherapy.

Secondary Outcome Measures

Name	Time	Method
1. The response of peritoneal carcinomatosis to chemotherapy according to RECIST criteria and postoperative pathological examination;<br /><br>2. Safety of neo-adjuvant chemotherapy and CRS+HIPEC with respect to 30-day or in-hospital mortality;<br /><br>3. Quality of life as measured by the EORTC-QLQ C30 quality of life questionnaire;<br /><br>4. Morbidity of surgery according to the NCI-CTC v4.0;<br /><br>5. The effect of chemotherapy and CRS with HIPEC on intestinal barrier function as measured by IFAB levels;<br /><br>6. The percentage of patients able to complete full treatment.